A U.S. government study finds that people who use GLP-1 drugs, including medications marketed as Ozempic and Wegovy, take less long-term sick leave than people who do not. According to the report, patients on GLP-1 treatments have 17% fewer illness-related absences lasting more than a specified duration, compared with non-users. The findings are published by the National Bureau of Economic Research. The coverage describes potential implications for both employees and employers, suggesting that reduced sick leave could translate into lower costs associated with workforce absences. CBS News and a separate roundup report both summarize the same core result: a measurable decrease in longer-term illness leave among GLP-1 users. While the reports focus on the sick-leave reduction and possible cost savings, they do not detail additional mechanisms or quantify overall financial impact. The study’s approach, definitions of sick leave, and the scope of the analysis are presented in general terms across the outlets, with further methodological details available in the published paper.